Physician profile
Olevia Metry
NPI 1205256328
$852.70
in general payments reported to CMS, 2019-2025
13 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.11 · 2020: $26.44 · 2021: $124 · 2023: $73.25 · 2024: $352 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $189.09 | 2021-2024 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $148.90 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $110.93 | 2025 | Zepbound |
| Pfizer INC. | $104.33 | 2024 | |
| Amgen INC. | $66.13 | 2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $61.96 | 2023-2024 | |
| Genentech USA, INC. | $39.73 | 2019-2020 | |
| Glaxosmithkline, LLC. | $33.64 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $26.67 | 2024 | |
| Tempus Ai, INC | $19.45 | 2024 | |
| Meridian Bioscience INC. | $18.82 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.66 | 2023 | Quviviq |
| Abbvie INC. | $16.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olevia Metry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.